Development of vaccines against human parasitic diseases: tools, current status and perspectives (Q34074704)

30 July 2017

1 reference

title

Development of vaccines against human parasitic diseases: tools, current status and perspectives (English)

1 reference

30 July 2017

Abath FG

1

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 February 2000

1 reference

Expert Opinion on Investigational Drugs

30 July 2017

published in

1 reference

30 July 2017

volume

9

1 reference

30 July 2017

issue

2

1 reference

30 July 2017

page(s)

301-310

1 reference

Six decades of vaccine development--a personal history

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Development of a safe live Leishmania vaccine line by gene replacement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Delivery of epitopes by the Salmonella type III secretion system for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Delivery of DNA vaccines by attenuated intracellular bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Gene vaccination: plasmid DNA is more than just a blueprint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

21 January 2018

Overview of DNA vaccines

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

A malaria vaccine based on a sporozoite antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Research toward vaccines against malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Strategy for development of a pre-erythrocytic Plasmodium falciparum DNA vaccine for human use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Predicted disulfide-bonded structures for three uniquely related proteins of Plasmodium falciparum, Pfs230, Pfs48/45 and Pf12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Transmission-blocking vaccines: uses and current status of development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Controlled field trials of a vaccine against New World cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Leishmania vaccines: old and new.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania 'major surface glycoprotein' (gp63).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Prospects for immunological control of schistosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Irridiated schistosome vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Protective immunity to Schistosoma mansoni induced in the olive baboon Papio anubis by the irradiated cercaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Schistosomiasis vaccine:research to development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Molecular cloning of a protective antigen of schistosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Paramyosin and actin in schistosomal teguments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Induction of protective immunity against Schistosoma mansoni by vaccination with schistosome paramyosin (Sm97), a nonsurface parasite antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

A Schistosoma mansoni fatty acid-binding protein, Sm14, is the potential basis of a dual-purpose anti-helminth vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

A dominant B-cell epitope on the 22 kDa tegumental membrane-associated antigen of Schistosoma japonicum maps to an EF-hand calcium binding domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Genetic immunization of mice with DNA encoding the 23 kDa transmembrane surface protein of Schistosoma japonicum (Sj23) induces antigen-specific immunoglobulin G antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Schistosome immunology: more questions than answers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Vaccines against human parasitic diseases: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

An IL-12-based vaccine approach for preventing immunopathology in schistosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.2.301

21 January 2018

Identifiers

DOI

10.1517/13543784.9.2.301

1 reference

30 July 2017

1 reference